IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 5.2% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings Inc. (IQV) is a company that provides advanced analytics, clinical research, and technology solutions for the life sciences industry. The company recently reported strong quarterly earnings, leading to a bullish movement in the stock market today.

Why is IQVIA Holdings Inc. going up?

IQV stock is up 5.2% on Feb 27, 2026 17:45

• Primecap Management Co. CA reduced its stake in IQVIA Holdings Inc., but other institutional investors increased their holdings, indicating varying sentiments among investors.
• The acquisition of drug discovery assets from Charles River Laboratories is seen as a strategic move to expand IQVIA's capabilities and enhance its early-stage research offerings, potentially boosting investor confidence.
• Analysts adjusting price targets for IQV post-earnings report and re-segmentation suggest a positive outlook for the company, with some considering it a strong buy despite potential competition from AI stocks.
• Broyhill Asset Management's endorsement of IQV as a top contributor to its portfolio highlights the company's strong performance and its resilience in the face of concerns over biotech funding and clinical activity, positioning it favorably in the market.

IQV Price Chart

IQV Technical Analysis

IQV News

Primecap Management Co. CA Has $89.11 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Primecap Management Co. CA recently reduced its stake in IQVIA Holdings Inc. by 13.7% in the third quarter, now holding 469,161 shares valued at $89.11 million. Despite this, other institutional investors have increased their holdings in IQVIA. The company reported strong quarterly earnings, topping analyst estimates, and has a "Moderate Buy" consensus rating from Wall Street analysts.

https://www.marketbeat.com/instant-alerts/filing-primecap-management-co-ca-has-8911-million-stock-holdings-in-iqvia-holdings-inc-iqv-2026-02-27/

Is IQVIA Holdings Inc. (IQV) a Buy Post Earnings?

Mizuho, Truist, and TD Cowen have adjusted their price targets for IQVIA Holdings Inc. (IQV) following its fiscal Q4 report and re-segmentation, with ratings ranging from Outperform to Hold. Analysts are considering the potential impact of AI disruption on the company, which provides advanced analytics, clinical research, and technology solutions for the life sciences industry. While IQV is seen as a strong buy by some, the article suggests that certain AI stocks may offer greater upside potential with less downside risk.

https://finviz.com/news/324686/is-iqvia-holdings-inc-iqv-a-buy-post-earnings

IQVIA to acquire Charles River drug discovery assets

IQVIA Holdings has signed an agreement to acquire selected drug discovery service assets from Charles River Laboratories, including five sites specializing in in vitro drug discovery and a small molecule AI platform. This acquisition aims to expand IQVIA's end-to-end capabilities, enhance its early-stage research offerings, and benefit pharmaceutical and biotech sponsors by integrating regulatory, scientific, and clinical knowledge. The transaction is expected to close in the second quarter.

https://www.pharmaceutical-technology.com/news/iqvia-acquire-charles-river-assets/

IQVIA Holdings (IQV) Rallied on Waning Concerns Over Biotech Funding and Clinical Activity

Broyhill Asset Management's Q4 2025 investor letter highlighted IQVIA Holdings Inc. (NYSE: IQV) as a top contributor to its portfolio, attributing its strong performance to easing fears around biotech funding and clinical activity. Despite the broader market's focus on AI, Broyhill maintains a contrarian strategy, believing IQV's role as a critical drug development infrastructure makes it a durable business with mispriced catalysts. The firm expects the recovery in the biotech sector to accelerate, further benefiting IQV.

https://www.insidermonkey.com/blog/iqvia-holdings-iqv-rallied-on-waning-concerns-over-biotech-funding-and-clinical-activity-1703811/

IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities

IQVIA has announced an agreement to acquire specific drug discovery assets from Charles River Laboratories. This acquisition will enhance IQVIA's existing capabilities, creating a fully integrated, end-to-end drug discovery platform. The move is expected to broaden IQVIA’s capacity to support early discovery research across various drug modalities and therapeutic areas, with the transaction anticipated to close in the second quarter.

https://www.biospace.com/press-releases/iqvia-signs-agreement-to-acquire-drug-discovery-assets-from-charles-river-laboratories-expanding-end-to-end-drug-discovery-capabilities

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.6% Today

Vornado Realty Trust ($VNO) Stock Forecast: Down 5.7% Today

Boston Properties Inc. ($BXP) Stock Forecast: Down 5.5% Today

PNC Financial Services Group Inc. (The) ($PNC) Stock Forecast: Down 5.0% Today

Fastly Inc. ($FSLY) Stock Forecast: Up 5.6% Today

Astera Labs Inc ($ALAB) Stock Forecast: Down 5.0% Today

Capital One Financial Corporation ($COF) Stock Forecast: Down 5.8% Today

Netflix Inc. ($NFLX) Stock Forecast: Up 13.9% Today

GitLab Inc. ($GTLB) Stock Forecast: Down 5.4% Today

Regions Financial Corporation ($RF) Stock Forecast: Down 5.3% Today

IQVIA Holdings Inc. Price History

26.01.2026 - IQV Stock was up 5.2%

• Today's positive movement for IQVIA is linked to its acquisition of drug discovery assets from Charles River Laboratories, enhancing its early-stage research offerings and drug discovery platform.
• The rally was also supported by improved investor sentiment on biotech funding and clinical activity, positioning IQVIA as a resilient business with growth opportunities.
• Despite some concerns about fundamental aspects like revenue growth and free cash flow margin, the market is optimistic about IQVIA's strong 2025 performance projections, including revenue and EPS growth, and collaborations in AI-driven research.
• Overall, IQVIA's bullish momentum reflects investor confidence in its acquisitions, financial performance, and growth potential in healthcare and biotech sectors.

13.01.2026 - IQV Stock was up 5.0%

• Despite concerns about margin compression, IQVIA's Q4 earnings call exceeded revenue expectations, leading to a positive market reaction.
• Analysts remain optimistic about IQVIA's future performance, with recent insider buying and a "Moderate Buy" rating indicating confidence in the company's growth potential.
• The company's focus on AI integration, strategic acquisitions, and addressing macroeconomic challenges demonstrates its commitment to long-term success, driving the bullish movement in its stock price today.

05.01.2026 - IQV Stock was down 6.6%

• Despite exceeding earnings forecasts and providing optimistic guidance for 2026, IQV's stock experienced a significant drop of 9.02% in pre-market trading.
• The market's reaction to IQV's strong financial performance could be attributed to broader market dynamics and concerns about the disruptive potential of AI technologies.
• While IQV showcased robust profitability and growth, the high debt-to-equity ratio and potential liquidity challenges highlighted in the analysis might have contributed to the bearish movement in the stock.
• CEO Ari Bousbib's emphasis on AI as a positive enabler for IQVIA's business, along with strategic acquisitions and AI advancements, could be key factors to monitor for potential market recovery.

05.01.2026 - IQV Stock was down 7.6%

• Despite strong financial performance in the fourth quarter, surpassing revenue projections, IQV encountered a downward trend in the market.
• The market decline may stem from concerns surrounding the company's high debt-to-equity ratio and potential liquidity issues, possibly overshadowing the positive financial results.
• Moreover, comparisons depicting IQV as a more attractive investment choice than Idexx Laboratories could have impacted investor confidence, leading to profit-taking or a shift in investment strategies.
• Investors appear wary leading up to the upcoming earnings release, seeking clarity on margin growth and new enterprise partnerships, particularly within the Technology & Analytics Solutions sector, amid budget constraints in the biotech industry.

12.01.2026 - IQV Stock was down 8.4%

• Amid Q3 earnings strength and upbeat FY2026 guidance, IQVIA Holdings Inc. (IQV) witnessed bearish movement likely attributed to:
• Decline in share price over three years, suggesting potential misvaluation or market influences.
• A recent 26% share price plunge after financial results release, causing investor apprehension.
• Price target cuts by analysts while maintaining a "Moderate Buy" rating, reflecting market uncertainty.
• Share price drop on February 10, indicating short-term selling pressure and market volatility.

12.01.2026 - IQV Stock was down 8.3%

• Despite strong Q3 earnings and positive FY2026 guidance, IQVIA Holdings' stock dropped by 26% post-financial results, indicating investor concerns.
• The discrepancy between the company's 11% annual EPS growth and the 22% decline in share price over a three-year period suggests potential misvaluation or underlying issues impacting investor sentiment.
• The recent acquisition of a significant number of IQVIA shares by Eubel Brady & Suttman Asset Management Inc. may indicate confidence in the company's long-term prospects, though market sentiment remains cautious.
• The overall bearish trend in IQV's stock could be linked to broader challenges in the medical research sector, illustrated by negative trends in competitors such as ICON plc and Charles River Laboratories International, influencing investor sentiment industry-wide.

11.01.2026 - IQV Stock was down 5.0%

• IQVIA stock saw significant downward movement during the trading day.
• The collaboration between IQVIA and the Duke Clinical Research Institute aimed at advancing clinical research in obesity and related conditions was well-received by investors.
• Despite the upbeat response to the research partnership, the stock's decline may be linked to a decrease in ownership by Compagnie Lombard Odier SCmA, suggesting waning confidence from some institutional investors.
• The overall market outlook for IQVIA is optimistic, with analysts upholding a "Moderate Buy" consensus rating and an average price target of $239.87, indicating potential growth despite today's market performance.

04.01.2026 - IQV Stock was down 13.6%

• IQV's stock price fell by 9.18% on February 3rd, closing at $210.00.
• Investor caution and profit-taking prior to the upcoming Q4 earnings report on February 5th likely contributed to this decline.
• Despite the recent drop, analysts are optimistic about IQV's future, suggesting potential for significant growth and indicating that short-term fluctuations may be causing an overreaction in the market.
• IQV's stock underperformance relative to industry competitors and broader market indices hints at broader market sentiment and sector-specific influences impacting the bearish movement.

10.01.2026 - IQV Stock was down 5.2%

• A strategic collaboration with the Duke Clinical Research Institute to advance clinical research in obesity and related conditions is expected to have a positive impact on the company's growth and its influence on patient therapies.
• The recent reduction in stake by Compagnie Lombard Odier SCmA and Thrivent Financial for Lutherans could have contributed to a bearish movement in the stock, potentially indicating profit-taking or a shift in investor sentiment.
• Despite surpassing earnings and revenue expectations in the last quarter and offering optimistic guidance for FY 2026, concerns regarding increased interest expenses and lowered price targets by analysts may have impacted the stock's performance.
• The general market sentiment towards IQVIA is cautiously optimistic, with a consensus rating of "Moderate Buy" and an average target price of $239.87, suggesting potential for recovery ahead.

27.01.2026 - IQV Stock was up 5.2%

• Primecap Management Co. CA reduced its stake in IQVIA Holdings Inc., but other institutional investors increased their holdings, indicating varying sentiments among investors.
• The acquisition of drug discovery assets from Charles River Laboratories is seen as a strategic move to expand IQVIA's capabilities and enhance its early-stage research offerings, potentially boosting investor confidence.
• Analysts adjusting price targets for IQV post-earnings report and re-segmentation suggest a positive outlook for the company, with some considering it a strong buy despite potential competition from AI stocks.
• Broyhill Asset Management's endorsement of IQV as a top contributor to its portfolio highlights the company's strong performance and its resilience in the face of concerns over biotech funding and clinical activity, positioning it favorably in the market.

03.01.2026 - IQV Stock was down 9.4%

• IQV experienced a bearish movement likely due to:
• Analysts' cautious outlook on the company's Q4 earnings despite a history of positive surprises.
• Institutional investors adjusting their positions, with Running Oak Capital LLC selling shares and others increasing stakes, possibly signaling mixed sentiments in the market.
• The broader market reaction to another company's decline post-earnings beat, indicating sector-wide concerns over future guidance and valuation.
• The AI-generated analysis pointing to weak near and mid-term sentiment, contributing to the negative market movement for IQV.

06.01.2026 - IQV Stock was up 5.4%

• Despite adjustments in price targets by various analysts, IQVIA Holdings (IQV) witnessed significant bullish movement in the market today.
• The market is responding positively to IQVIA's robust performance in Q4 2025, surpassing revenue projections and demonstrating a commitment to AI-driven solutions for future expansion.
• Analysts' concerns regarding margin pressures and sustainability of growth have been somewhat overshadowed by the company's strategic acquisitions, streamlined business operations, and optimistic 2026 forecast.
• Investors appear to find IQVIA Holdings' current valuation appealing for potential growth opportunities, despite short-term challenges highlighted by analysts.